Oncomine Comprehensive Assay
A comprehensive NGS-based genomic profiling test that detects clinically significant DNA and RNA alterations across cancer-related genes, including SNVs, indels, CNVs, gene fusions, MSI, and TMB, to support precision oncology treatment decisions.
Clinical Insight
Understanding The Assay
The Oncomine Comprehensive Assay is a next-generation sequencing test designed to profile solid tumors for clinically relevant genomic alterations. By analyzing both DNA and RNA from a single tissue sample, it identifies single nucleotide variants, insertions and deletions, copy number variations, and gene fusions across hundreds of cancer-associated genes.
Depending on the panel selected, the assay also reports microsatellite instability and tumor mutational burden status.
This broad molecular profile helps oncologists match patients to targeted therapies, clinical trials, and immunotherapy options with greater precision. Using a single FFPE tissue sample, the test conserves valuable specimen material while delivering a comprehensive view of the tumor's genomic landscape to guide treatment planning.
Clinical Applications
Identifies clinically actionable mutations and fusions, matching patients to approved and investigational targeted therapies based on their tumor's genomic profile.
Clinical Applications
Reports instability status and tumor mutational burden, key biomarkers helping clinicians assess patient eligibility for checkpoint inhibitor and advanced therapy options.
Analyzes DNA and RNA from a single FFPE sample, detecting SNVs, indels, CNVs, and fusions across hundreds of cancer-related genes.
Uncovers rare, actionable variants that connect patients to relevant clinical trials, expanding options beyond standard-of-care treatment pathways.
Testing Benefits
Benefits Built For Precision Oncology
Comprehensive Genomic Coverage
Screens 500+ or 161 genes depending on panel selection, detecting SNVs, indels, CNVs, and gene fusions in a single assay.
Precision Medicine Support
Delivers detailed molecular insights that help oncologists move beyond generic protocols toward treatment plans tailored to each patient's tumor.
Targeted Therapy Selection
Identifies actionable genomic alterations that match patients to approved and investigational targeted therapies suited to their specific tumor profile.
Expanded Test Reporting
Reports MSI and tumor mutational burden alongside genomic alterations, providing added biomarkers relevant to treatment planning and clinical decisions.
Single-Sample Efficiency
Analyzes both DNA and RNA from a single FFPE tissue sample, conserving valuable specimen material while maximizing diagnostic yield.
Comprehensive Molecular Profiling
Combines multiple alteration types into one assay, delivering a complete genomic picture to support informed, confident treatment decisions.
Schedule Your Test
Partner with our team to schedule tumor profiling and gain expert guidance on treatment-relevant genomic insights.
